- AptarGroup’s adjusted EPS for the fourth quarter was $1.52, exceeding both the previous year’s $1.21 and the estimate of $1.26.
- Net sales were recorded at $848.1 million, a 1.1% increase from the previous year but slightly below the expected $854.4 million.
- Pharma net sales reached $400.7 million, up by 4.1% year over year, though short of the $413 million estimate.
- The company reported an adjusted EBITDA of $194.9 million, which is 8.6% higher than last year and above the $183.2 million estimate.
- Pharma’s adjusted EBITDA came in at $143.1 million, marking a 9.1% increase and beating the estimate of $139.5 million.
- AptarGroup achieved an adjusted EBITDA margin of 23%, surpassing the estimated 21.6% margin.
- Beauty segment sales dropped by 4.8% to $274.1 million, against an estimate of $277.8 million.
- Closures segment sales increased by 4.6% to $173.3 million, outperforming the $171.5 million estimate.
- Beauty segment’s adjusted EBITDA fell by 20% to $33.9 million, missing both estimates of $41.5 million.
- Closures adjusted EBITDA surged by 25% to $27.9 million, exceeding the $25.6 million estimate.
- AptarGroup’s forecasted earnings per share for Q1 2025 is projected to be between $1.11 and $1.19, excluding specific expenses and costs.
- The company remarked on an improvement in the beauty segment’s margin, attributing it to enhanced productivity and cost management.
- Analyst ratings: 7 buys, 2 holds, and 0 sells.
Aptargroup Inc on Smartkarma
On Smartkarma, Aptargroup Inc has caught the attention of analysts like Baptista Research. In their report titled “AptarGroup Inc.: Strengthening Market Position in Beauty & Personal Care & Expansion in Proprietary Drug Delivery Systems As Critical Growth Levers! – Major Drivers,” the earnings call for the third quarter showed a 2% core sales growth and a 15% EPS growth for the first nine months of the year. The report highlighted robust segments for growth and the company’s strategic plans for efficiency and market expansion until 2025, with an impressive Adjusted EBITDA margin reaching the higher end of the long-term target at 23%.
In another insightful report by Baptista Research, “AptarGroup Inc.: An Insight Into Their Core Business Strategy! – Major Drivers,” Aptar’s strong performance in dispensing and drug delivery solutions is emphasized. With a 3% core sales growth and adjusted EPS of $1.37 in the second quarter of 2024, marking a 12% increase over the previous year, the company’s positive momentum continued. The report underlined the significant demand for pharma proprietary drug delivery systems and overall margin improvements that contributed to a dividend increase of around 10% recently announced by the company.
A look at Aptargroup Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Aptargroup Inc is positioned favorably for long-term growth. With a solid overall outlook, the company scores well in Growth, indicating strong potential for expansion and development in the coming years. Additionally, Aptargroup Inc demonstrates resilience and momentum in its operations, with consistent performance and a positive trend in market presence. While the Value score is moderate, the company maintains a competitive edge in the market through its diverse range of products used across various sectors.
Aptargroup Inc, a global leader in designing and manufacturing pumps, dispensing closures, and aerosol valves, caters to a wide range of industries including fragrance/cosmetics, personal care, pharmaceutical, household/industrial, and food products. Operating on a worldwide scale, Aptargroup Inc‘s strategic positioning and strong performance in growth, resilience, and momentum bode well for its long-term outlook, making it a promising prospect for investors seeking steady growth potential in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
